Gastrointestinal Cancer News

Early-onset colorectal cancer appears to have different clinical and genetic characteristics than colorectal cancer diagnosed later in life, according to results of a retrospective study published in Cancer.

A mobile bus that has been used to offer women breast cancer screening in rural parts of West Virginia may help test the efficacy of a novel blood test to screen for colorectal cancer, according to a press release.

Genetic variations in the catechol-O-methyltransferase gene appeared to influence whether vitamin E supplements decreased or increased the risk for developing cancer, according to results of a retrospective study published in Journal of the National Cancer Institute.

March is Colorectal Cancer Awareness Month. First designated by President Clinton in 2000, this initiative has become an important catalyst for patients, survivors, physicians and advocates to raise awareness about the importance of getting screened.

Researchers from the University of Pittsburg Medical Center have found specific genetic mutations that revealed which pancreatic cancer tumors could be susceptible to existing chemotherapy drugs, according to an analysis published in Gastroenterology.

Researchers at University of Colorado Cancer Center and partnering institutions received a grant to study a novel combination therapy for patients with microsatellite-stable metastatic colon cancer.

A watch-and-wait strategy for certain patients with rectal cancer who achieved clinical complete response following neoadjuvant therapy yielded high rates of rectal preservation and pelvic tumor control, according to a recent study published in JAMA Oncology.

Analyzing volatile organic compounds found in fecal samples could aid in the diagnosis of colorectal adenocarcinoma, according to research published in Alimentary Pharmacology & Therapeutics.

A restrictive protocol safely and effectively reduced the number of opioids prescribed to patients who underwent gynecologic or abdominal surgery, according to findings from a 2-year pilot case-control study.

More than 2 million Americans have been screened for colorectal cancer with Cologuard since the stool-based DNA test received FDA approval in 2014, according to a company press release.